Eskow Jaunarajs K L, Bonsi P, Chesselet M F, Standaert D G, Pisani A
Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, USA.
IRCCS Fondazione Santa Lucia, Laboratory of Neurophysiology and Plasticity, Rome, Italy.
Prog Neurobiol. 2015 Apr;127-128:91-107. doi: 10.1016/j.pneurobio.2015.02.002. Epub 2015 Feb 17.
Dystonia is a movement disorder of both genetic and non-genetic causes, which typically results in twisted posturing due to abnormal muscle contraction. Evidence from dystonia patients and animal models of dystonia indicate a crucial role for the striatal cholinergic system in the pathophysiology of dystonia. In this review, we focus on striatal circuitry and the centrality of the acetylcholine system in the function of the basal ganglia in the control of voluntary movement and ultimately clinical manifestation of movement disorders. We consider the impact of cholinergic interneurons (ChIs) on dopamine-acetylcholine interactions and examine new evidence for impairment of ChIs in dysfunction of the motor systems producing dystonic movements, particularly in animal models. We have observed paradoxical excitation of ChIs in the presence of dopamine D2 receptor agonists and impairment of striatal synaptic plasticity in a mouse model of DYT1 dystonia, which are improved by administration of recently developed M1 receptor antagonists. These findings have been confirmed across multiple animal models of DYT1 dystonia and may represent a common endophenotype by which to investigate dystonia induced by other types of genetic and non-genetic causes and to investigate the potential effectiveness of pharmacotherapeutics and other strategies to improve dystonia.
肌张力障碍是一种由遗传和非遗传因素引起的运动障碍,通常由于异常的肌肉收缩导致姿势扭曲。来自肌张力障碍患者和肌张力障碍动物模型的证据表明,纹状体胆碱能系统在肌张力障碍的病理生理学中起关键作用。在这篇综述中,我们聚焦于纹状体神经回路以及乙酰胆碱系统在基底神经节控制自主运动及最终运动障碍临床表现功能中的核心地位。我们考虑胆碱能中间神经元(ChIs)对多巴胺 - 乙酰胆碱相互作用的影响,并研究在产生肌张力障碍性运动的运动系统功能障碍中,尤其是在动物模型中,ChIs受损的新证据。我们在DYT1肌张力障碍小鼠模型中观察到,多巴胺D2受体激动剂存在时ChIs出现反常兴奋,以及纹状体突触可塑性受损,而最近开发的M1受体拮抗剂给药可改善这些情况。这些发现已在多个DYT1肌张力障碍动物模型中得到证实,可能代表一种常见的内表型,借此可研究由其他类型遗传和非遗传原因引起的肌张力障碍,并研究药物治疗和其他改善肌张力障碍策略的潜在有效性。